article

Drug Target Review – Issue 3 2021

Posted: 22 September 2021 | | No comments yet

In this issue, find articles exploring why CRISPR is useful for high-throughput drug discovery, how targeting telomerase may lead to universal cancer vaccines and a new study to identify therapeutics that can be repurposed against COVID-19. Also included are features on neuroscience, organoids and antibodies. 

DTR Issue 3 2021

Included in this issue:

  • VACCINE DEVELOPMENT
    An integrated vaccination approach to neurodegeneration

    Dr Andrea Pfeifer, AC Immune
  • NEUROSCIENCE
    Using brain models of patient-specific Alzheimer’s insights
    Victoria Rees, Drug Target Review
  • SYNTHETIC BIOLOGY
    The diversity of synthetic biology applications
    Dr Jim Collins, MIT and Wyss Institute at Harvard University
  • ORGANOIDS
    High-throughput 3D cell migration assays in organ-on-a-chip technologies
    Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek, MIMETAS
  • ANTIBODIES
    An IgM antibody platform to tackle SARS‑CoV-2 and its variants
    Dr Steve Carroll, IGM Biosciences
  • TARGETS
    Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
    Dr Chetan Karyekar, Janssen
  • ASSAYS
    Improving drug discovery with advanced targeted proteomic monitoring workflows
    Professor Forest White, MIT
    Dr Lauren Stopfer, BioNTech

The rest of this content is restricted - login or subscribe free to access

DTR Issue 3 2021 MiniMagThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here